FinancialNewsMedia.com News Alert: NEW YORK, (http://www.financialnewsmedia.com News Alert) – NetworkNewsWire Editorial Coverage: The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (NYSE: IGC) IGC Profile – https://www.networknewswire.com/clients/india-globalization-capital-inc-igc/?symbol=igc, Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), OWC Pharmaceutical Research Corp. (OTC:OWCP), Insys Therapeutics, Inc. (NASDAQ: INSY) and GW Pharmaceuticals plc (NASDAQ: GWPH) are carving lanes of unprecedented opportunities in the medical field.
Bethesda, Maryland-based India Globalization Capital (NYSE: IGC) (IGC Profile) is advancing the development of cannabis-based therapies targeting large market conditions and illnesses. IGC is on a mission to treat chronic and terminal neurological and oncological diagnoses and other life altering conditions utilizing an exciting and specialized IP platform that formulates and tests combination therapies. With this special focus in mind, IGC has amassed a portfolio of patent filings covering the indications of pain, medical refractory epilepsy and cachexia (cancer-induced anorexia) using cannabinoids. As we will further discuss later, IGC has established an approach that significantly differentiates the company from its cannabis-pharma peers.
Like IGC, Zynerba Pharmaceuticals (NASDAQ: ZYNE) is dedicated to the development of innovative cannabinoid treatments that target seizures and pain. Unlike IGC and Cannabics, this clinical-stage, specialty pharmaceutical company is concentrating on developing transdermal synthetic cannabinoid treatments. On March 13, 2017, the company announced that it had completed enrolling patients for Phase 2 of its STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy…